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Abstract: 
Cosmetic dermatology is a marriage between medicine and business. 
Research in cosmetic dermatology shares the fundamental principles of 
clinical and pharmaceutical research. Research team can help the 
decision makers by giving a realistic picture of the uncertainties 
involved. Certain mathematical models and market research techniques 
can aid decision making. 
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Introduction 
 
Cosmetic dermatology is a unique specialty where clinical medicine 
has a legitimate but often detested relationship with business. There are 
people lined up on either side of the hazy line between medicine and 
business, each group trying to understand the other. True clinical 
dermatologists consider cosmetic dermatology an imprecise and vague 
specialty.(1)  
 
A cosmeceutical, is conventionally defined as a cosmetic product 
claimed to have drug-like properties.(2) The term cosmeceutical is a 
portmanteau of the words "cosmetic" and "pharmaceutical” and is not 
recognized by Food and Drug Administration (FDA). A cosmeceutical 
is not subject to FDA review and approval processes.(3) Medical 
devices used in cosmetic dermatology range from cautery machines to 
lasers. Injectable enhancement products like Botox®(4) and dermal 
fillers are also popular. The Division of General, Restorative and 
Neurological Devices (DGRND) within FDA regulates most of the 
medical devices and injectable dermal fillers used by 
dermatologists.(5) In this article the term “cosmeceutical” is used to 
represent cosmetic products, injectable products and medical devices 
(like microdermabrasion and laser machines) used in cosmetic 
dermatology.  
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The pharmaceutical research paradigms of target identification, 
screening, lead optimization and clinical trials from phase I to IV do 
not directly apply in cosmeceutical research.(6) In pharma the industry 
decides what is good for the patient where as in cosmetic dermatology 
the patient decides what is good for him/her. Hence it is not imperative 
that a significant placebo effect be identified and accounted for even if 
it arises from a dominant bias. A typical example is Laser Hair 
Reduction. It is very difficult to conclusively prove that it is more 
effective than any other hair removal method to justify its cost. But it is 
a billion dollar industry and is considered a ‘successful technology’ in 
cosmeceutical arena.(7) 
 
This article is an attempt to reconcile research in cosmetic dermatology 
with business and market research. First we discuss the basic 
requirements for clinical research in cosmetic dermatology. Then we 
move on to the uncertainties faced by decision makers and the 
mathematical models which may be of help in solving them. Finally 
we briefly discuss the market research techniques used in 
cosmeceutical industry. 
 
Requirements for research in cosmetic dermatology 
 
The term research has a different meaning in cosmeceutical industry. 
Some big organisations use the term for product or service 
improvement. Optimization of existing technology for specific needs 
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(not necessarily different indications) is a common practice in 
cosmeceutical industry. Each organization conducts its on research for 
optimizing the technology. As this is often conducted without a proper 
understanding of clinical research paradigms, certain errors of 
judgment are frequently encountered.  
 
THE NEED TO COMPARE 
It is always worthwhile to compare new technologies to already 
available ones in terms of efficacy and adverse effects. For example 
several depigmenting agents are known with varying levels of efficacy. 
When a new and more expensive product combination is introduced, it 
is important to compare it with individual components used alone to 
justify the cost of the combination. However the decision of whether to 
adopt a new technology should not be based entirely on the results of 
comparison. But the comparison will give clear indications about the 
likely success and the potential problems during introduction and has 
substantial marketing value. 
 
THE NEED TO RANDOMIZE 
Randomization is given due importance in pharma trials. But many 
cosmeceutical researchers rely on a ‘study group cohort ‘rather than 
random sample. The active ingredient, vehicle or even contaminants in 
a cosmeceutical can cause an allergic or irritant reaction in a small 
percentage of users.(8) Manufacturers try to assess the risk during the 
trial period. If the trials are conducted on the same group always, the 
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group undergoes a natural selection process as those who develop a 
reaction are unlikely to report for further trials. The results on this 
‘thick skinned’ cohort cannot be reliably extended to the general 
population. 
 
THE NEED FOR BLINDING 
Blinding is another important concept often ignored in cosmeceutical 
research. Sometimes blinding can be difficult or impossible to 
implement especially for those trials involving machines. Hence most 
of the studies are plagued by researcher as well as subject bias. This 
bias gets confounded several times when the researchers also become 
part of the study group, a practice common in cosmeceutical research. 
Individual service providers often comment that they have tried the 
product or service on themselves and found it to be safe and effective. 
Having an independent blinded observer who does majority of 
assessment can significantly reduce the bias. But bias cannot be 
completely removed from study design in cosmeseutical research and 
should be kept in mind during final evaluation. 
 
THE NEED FOR OBJECTIVE ASSESSMENT 
The assessment is often subjective in cosmeceutical research. The 
unavoidable biases along with subjective assessment methods make the 
studies less credible. It is important to make full use of new, objective 
assessment techniques involving computer assisted image analysis and 
optical spectroscopy. Computer assisted image analysis is the 
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computational extraction of meaningful information from digital 
images by pattern recognition and digital geometry.(9) Optical 
spectroscopy involves study of scattering and reflectance pattern of the 
skin for an objective assessment of appearance. (10) 
 
THE NEED TO USE MOLECULAR AND CELL BIOLOGY 
TECHNIQUES 
The chance of success for a cosmeceutical is likely to be higher if it 
has a strong basis in molecular and cell biology. Ingredients developed 
on the basis of its effect on well characterized molecular targets are 
more likely to be successful. The new generation growth factors and 
aquaporin modulators are typical examples.(11) The recent 
developments like in vitro human skin helps in assessing the efficacy 
and adverse effects of cosmeceuticals in a more objective and safe 
way.(12) 
 
THE NEED TO CONSIDER SKIN AND LIFE-STYLE 
VARIATIONS 
The importance of skin type in the choice of cosmeceuticals is well 
known. Certain lasers are considered not safe on darker skin as the 
chances of developing adverse effects are more.(13) The environment 
and life style can also have a significant effect on skin biophysical 
characteristics. Hence it is important to account for these confounding 
factors in study designs especially for those cosmeceuticals promoted 
as suitable for all skin types. 
 8 
 
 
THE NEED FOR LONG TERM FOLLOW-UP 
Since cosmeceuticals are not strictly regulated, products are introduced 
based on studies conducted for a few days or weeks or at most a few 
months. Since a watchdog like FDA is not present, certain technologies 
are introduced into the market without enough studies to back the 
safety claims of manufacturers. Often the user is not even aware of this 
fact. Permanent dermal fillers are a typical example.(14) It is known 
that foreign bodies can elicit a tissue reaction after prolonged periods 
of exposure. Hence short term safety of dermal fillers does not 
guarantee its long term safety after several injections. Long term 
follow-up studies are lacking for many dermal filler materials. The 
same applies to other techniques like laser as well. 
 
Uncertainties in decision making 
 
Once the researchers estimate the efficacy and safety of a 
cosmeceutical it is the turn of the decision makers to decide when, 
where and how to introduce the product in the market. The researcher, 
who is only aware of the net present value of the solution he offers, 
sees any delay in introduction as a strategic mistake. However the 
decision makers have to cope with the limitations of this approach and 
have to deal with several uncertainties. The researcher can be of 
assistance in gauging these uncertainties. The next section deals with 
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certain techniques for decision making in the context of 
cosmeceuticals.  
 
THE TECHNOLOGY UNCERTAINTY 
In simple terms ‘technology uncertainty’ means today’s gold standard 
may not be the ideal option tomorrow. For example the fractional 
technology superseded many existing laser technologies for a variety 
of indications.(15, 16) It is difficult to predict the viable life span of an 
existing technology. However a critical inspection of the evolution of 
the technology gives valuable hints to this. For example laser is a 
technology with high level of uncertainties where as an AHA peel is a 
more stable technology with only minor modification over a period of 
time. 
 
THE MARKET UNCERTAINTY 
The success of a technology depends not just on the efficacy and safety 
of the product, but also on a variety of other market related factors like 
cost, availability, ease of administration and advertisements. There are 
restrictions on advertisement for certain technologies in certain places. 
The insurance companies also add to this type of uncertainty. Any 
decision by an insurance company to reimburse a particular technology 
will tilt the balance in its favour.  
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THE COURSE UNCERTAINTY 
Keeping track of the long term safety of cosmeceuticals is important. 
However researchers in cosmetic dermatology have the habit of 
assuming long term safety based on few instances of safe use. The 
research team should be able to give a frank estimate of encountering 
an exception to the decision makers. This will prevent the decision 
makers from being Bertrand Russell's inductivist turkey. This fable 
relates the ‘error of induction’ to that of a turkey, fattened by its owner, 
is led to believe in the persistence of its life of prosperity, only to be 
slaughtered at Christmas.  
 
THE COMPETITION UNCERTAINTY 
When an organization plans the adoption of a new technology, it is 
important to consider how easy it would be for the competitors to 
acquire the same technology. Successful technologies will be quickly 
adopted by competitors thereby reducing the revenue from the 
particular stream. Competition uncertainty is low with new inventions 
which can be patented. Hence large organizations should promote 
inventions though novel inventions seldom happen. Novelty factor is 
important in cosmeceutical industry as new technologies tend to fetch 
more revenue initially. But it is important not to project initial success 
to future. 
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THE SOCIAL UNCERTAINTY 
The social uncertainty is an important factor in cosmeceuticals. A shift 
of social concerns can affect the popularity of certain cosmeceuticals. 
The increased awareness of the carcinogenic potential of UV has made 
sunscreens extremely popular while the popularity of tanning products 
has decreased with time. The depigmenting ‘fairness’ solutions are 
very popular in certain parts of the world.  
 
THE MANPOWER UNCERTAINTY 
Manpower uncertainty refers to the uncertainties in providing staff 
training or uncertainties in acquiring sufficiently trained personnel. 
Certain technologies which are training intensive tend to have more 
steps and are difficult to be standardized. Large providers try to 
maintain a six sigma quality for consistency in cosmetic service 
delivery. ‘Six sigma’ is a statistical concept which implies that if 
variations are kept to a minimum, few services fail to meet 
specifications. (17) 
 
Mathematical Models for decision making 
 
The above mentioned uncertainties make the decision makers’ job 
difficult. The research team can chip in by providing a fair assessment 
of the above uncertainties. Though decision making to a great extent is 
intuitive and comes from experience, there are certain objective 
techniques which may be of significant help.  
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HOW TO DELAY: THE REAL OPTIONS PARADIGM (18) 
The uncertainties can be reduced by delaying the exercise of an option. 
‘Real options’ is a technique to mathematically evaluate the worth of 
initiating, abandoning, slowing down or speeding up the introduction 
of a cosmeceutical. ‘Real options’ is based on the option pricing theory 
and is traditionally used in the trading of stocks. It can also be used in 
comparing the worth of two or more solutions (portfolio of options) for 
the same concern to decide which one to pursue. Any further 
discussion of Real options is beyond the scope of this article.  
 
 
HOW TO COMPETE: THE GAME THEORY PARADIGM (19) 
Game theory is a branch of applied mathematics to analyse strategic 
situations, in which an individual's success in making choices depends 
on the choices of others. As far as competing with other providers are 
concerned, it may be appropriate to have a ‘cooperative game’ model 
with each concentrating on their area of expertise rather than 
encroaching on competitors area of expertise. For example if your 
existing competitor specialises in invasive techniques like Botox® or 
fillers, it may be better to concentrate on other niche areas like laser. 
 
HOW TO PRIORITIZE: THE BAYESIAN PARADIGM (20) 
A modified Bayesian probabilistic model called ‘influence diagrams’ 
can be useful for solving decision-making problems. Influence diagram 
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graphically represents decisions, uncertainties and objectives and their 
connections and is a compact representation of a decision tree. It can 
help the decision maker to effectively communicate with the research 
team and to prioritize steps to maximise value.  
 
The simple influence diagram depicted in figure 1 represents the 
summary of what we have discussed so far. The success of the clinical 
research influences the decision to launch a product or service along 
with the competition and market uncertainties. All these factors 
influence the market value. 
 
Market Research for decision making (21) 
 
Understanding the market and subsequent regular monitoring of 
market trends are very important for decision makers. Qualitative and 
quantitative techniques can be used for market research in 
cosmeceutical industry.  
 
QUALITATIVE METHODS 
Qualitative methods include focus-group discussions and in-context 
interviews. Focus group discussions typically involve a small group of 
people brought together and asked to discuss certain topic. Focus 
group discussions help in identifying market trends. In-context 
interviews are conducted when a service is being performed or while 
using a product. In context interviews provide insight into favourable 
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product attributes. Analysis of data from qualitative techniques can be 
tricky. For example it is difficult to assess whether the clients give 
more importance to the cost or the effect of a service or product. 
Statistical techniques like conjoint analysis can be used to determine 
how clients prioritize product or service attributes.  For conjoint 
analysis a set of potential products or services is shown to clients. 
Clients are asked to arrange the set in the order of their preference. The 
importance of each factor can be computed from the responses by 
conjoint analysis. 
 
QUANTITATIVE METHODS 
Examples for quantitative tests include blind tests and usage tests. In 
blind test the participants are asked compare two products without 
revealing the brand. In usage test the participants are aware of the 
brand and the concept before they use the cosmeceutical. The number 
of participants is large and the quantitative data can be analysed using 
statistical tests and the results are representative of the total target 
population. Electronic medical records (EMR) and billing software 
also provide pertinent quantitative data important for assessing the 
long term performance of a product or service.(22) 
 
Conclusion: 
Research in cosmetic dermatology makes use of the same tools and 
principles of pharmaceutical research though the application may be 
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different. Research team in cosmetic dermatology has to liaise 
effectively with the decision makers and the marketing team. 
 
 16 
References: 
1. Dogra S. Fate of medical dermatology in the era of cosmetic dermatology and 
dermatosurgery. Indian J Dermatol Venereol Leprol 2009;75(1):4-7. 
2. Kligman D. Cosmeceuticals. Dermatol Clin 2000;18(4):609-15. 
3. Millikan LE. Cosmetology, cosmetics, cosmeceuticals: definitions and 
regulations. Clin Dermatol 2001;19(4):371-4. 
4. Eapen BR. Molecular biology of botulinum neurotoxin serotype A: a cosmetic 
perspective. J Cosmet Dermatol 2008;7(3):221-5. 
5. Dang JM, Krause D, Felten RP, Luke MK. Medical device regulation: what a 
practicing dermatologist should know. Dermatol Ther 2009;22:241-245. 
6. Fischer HP, Heyse S. From targets to leads: the importance of advanced data 
analysis for decision support in drug discovery. Curr Opin Drug Discov Devel 
2005;8(3):334-46. 
7. Preston PW, Lanigan SW. Patient satisfaction with laser hair removal. J 
Cosmet Dermatol 2003;2(2):68-72. 
8. Tomar J, Jain VK, Aggarwal K, Dayal S, Gupta S. Contact allergies to 
cosmetics: testing with 52 cosmetic ingredients and personal products. J 
Dermatol 2005;32(12):951-5. 
9. Bielfeldt S, Buttgereit P, Brandt M, Springmann G, Wilhelm KP. Non-
invasive evaluation techniques to quantify the efficacy of cosmetic anti-
cellulite products. Skin Res Technol 2008;14(3):336-46. 
10. Tseng SH, Grant A, Durkin AJ. In vivo determination of skin near-infrared 
optical properties using diffuse optical spectroscopy. J Biomed Opt 
2008;13(1):014016. 
 17 
11. Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular 
mechanisms. J Cosmet Dermatol 2007;6(2):75-82. 
12. Mun GC, Aardema MJ, Hu T, Barnett B, Kaluzhny Y, Klausner M, et al. 
Further development of the EpiDerm 3D reconstructed human skin 
micronucleus (RSMN) assay. Mutat Res 2009;673(2):92-9. 
13. Yee S. Laser hair removal in Fitzpatrick type IV to VI patients. Facial Plast 
Surg 2005;21(2):139-44. 
14. Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse 
effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical 
findings, long-term follow-up and review of the literature. J Eur Acad 
Dermatol Venereol 2008;22(2):150-61. 
15. Walgrave SE, Ortiz AE, MacFalls HT, Elkeeb L, Truitt AK, Tournas JA, et al. 
Evaluation of a novel fractional resurfacing device for treatment of acne 
scarring. Lasers Surg Med 2009;41(2):122-7. 
16. Rahman Z, MacFalls H, Jiang K, Chan KF, Kelly K, Tournas J, et al. 
Fractional deep dermal ablation induces tissue tightening. Lasers Surg Med 
2009;41(2):78-86. 
17. Dahl OJ. Six Sigma and modifications to gain an efficient practice. J Med 
Pract Manage 2008;24(2):88-90. 
18. Williams DR, Hammes PH. Real options reasoning in healthcare: an 
integrative approach and synopsis. J Healthc Manag 2007;52(3):170-86; 
discussion 187. 
19. Sanfey AG. Social decision-making: insights from game theory and 
neuroscience. Science 2007;318(5850):598-602. 
 18 
20. Scott GC, Shachter RD. Individualizing generic decision models using 
assessments as evidence. J Biomed Inform 2005;38(4):281-97. 
21. Mariampolski H. Qualitative Market Research: A Comprehensive Guide. 
Thousand Oaks, CA: Sage Publications; 2001. 
22. Eapen BR. Informatics in Clinical Practice Monitoring and Strategic Planning. 
MEJFM 2006;4(5):44-47. 
 
 19 
Figure 1.  A typical influence diagram 
 
 
